[Development of an animal model of blood stasis syndrome and thrombosis].
OBJECTIVE
To develop an animal model of thrombosis and blood stasis syndrome in rats by using lipopolysaccharide (LPS) in combination with carrageenan (Ca).


METHODS
SD rats in control group were randomly divided into control group and model group (LPS/Ca treatment). The rats in model group were firstly treated with Ca ip, and followed by LPS iv sixteen hours later. The rats in control group were given normal saline (NS). The moment of LPS iv was served as 0 h for the observation. The ear microcirculation, blood rheology parameters (whole blood viscosity etab, plasma viscosity etap and platelet aggregation PA), cruor parameters (thrombin time TT, prothrombin time PT, and partial thromboplastin time APIT) and inflammation factors (TNFalpha, IL-6) were observed at different time after treatment.


RESULTS
LPS/Ca combinatory treatment can induce a stable and repeatable thrombosis animal model. The thrombus can be observed on the tails of rats by naked eyes, and can be quantitatively measured without necessary of autopsy. Obstacle in microcirculation, increase in whole blood viscosity (etab) and a change of platelets aggregation (PA) rate were observed after LPS/Ca treatment. Cruor parameters were significantly prolonged due to large consumption of cruor factors and platelets. The concentration of inflammation factors TNFalpha and IL-6 in blood was obviously increased at the early stage of the model. The results indicate that this animal model has the characteristics of blood stasis syndrome caused by pyrogen and toxin accompanied by thrombosis.


CONCLUSIONS
LPS/Ca combinatory treatment can induce a easily practicable and repeatable animal model characterized as thrombosis and blood stasis syndrome
Liang
Ai-hua
AH
Institute of Chinese Materia Medica, China Academy of Traditional Chinese Medicine, Beijing 100700, China. liangaihua@sina.com
Ding
Xiao-shuang
XS
Li
Wen
W
Xue
Bao-yun
BY
Wang
Jin-hua
JH
Yang
Hong-jun
HJ
D000818:Animals; D001778:Blood Coagulation Disorders / Q000097:blood / Q000139:chemically induced*; D001809:Blood Viscosity; D002351:Carrageenan; D004195:Disease Models, Animal; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides; D008297:Male; D008833:Microcirculation; D010974:Platelet Aggregation; D011517:Prothrombin Time; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013918:Thrombin Time; D013927:Thrombosis / Q000097:blood / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D002351:Carrageenan